The PDRN market is rapidly expanding, prompting domestic pharmaceutical and biotech companies to enter the field. PharmaResearch has been leading the market focused on medical beauty, while new entrants are leveraging their research and development capabilities to broaden their reach into cosmetics and medical beauty.
According to market research firm Market Intel, the global PDRN market is projected to grow at an average annual rate of 12.8%, expanding from approximately $1.2 billion in 2025 to $3.1 billion by 2034.
The growth drivers have also diversified. Currently, about 58% of the PDRN market is comprised of injectables, but skincare products such as serums, creams, and masks are experiencing rapid growth, with an annual growth rate exceeding 14%. The expansion of online platforms and direct sales channels is further broadening the market's scope.
In South Korea, PharmaResearch is recognized as a leading company. The firm has expanded its PDRN and PN market with its beauty injectables 'Rejuran' and joint injection 'Conjuran,' and has developed a portfolio that encompasses both medical beauty and cosmetics with 'Rejuran Cosmetic.'
Park Jong-hyun, a researcher at Daol Investment & Securities, stated, "Investments in Rejuran branding and marketing have translated into growth in the cosmetics sector. The trend of increasing dermatology consumption is expected to continue alongside the expansion of medical tourism."
PDRN has been used in treatments for difficult-to-heal wounds, such as burns, and in regenerative medicine. The quality can vary based on the raw material and extraction and purification processes, making manufacturing technology crucial in this field.
A representative from PharmaResearch noted, "We were the first in Korea to initiate research and commercialization of salmon-derived PN and PDRN, managing the entire process from raw material acquisition to extraction and purification. We implement a unique purification method that does not use surfactants and utilize our proprietary platform, DOT, to ensure stable DNA raw materials."
As the applications of PDRN expand, companies are adopting diverse strategies. Hanmi Science, the holding company of Hanmi Pharmaceutical Group, recently launched a premium derma cosmetic brand 'ADESII.' This brand is based on the company's R&D capabilities, with a focus on a patented raw material 'H-EGTI.' The brand plans to expand its product line sequentially, starting with the 'Black Pearl PDRN Neo Serum' aimed at whitening, wrinkle improvement, and lifting.
Daewoong Pharmaceutical is also expanding its PDRN business through its affiliate, CJ Bio. CJ Bio is developing a PDRN-based skin booster 'Declassy PDRN,' focusing on reducing pain, embossing, and nodule concerns during injection. Clinical trials are currently underway, with a goal for release next year.
CJ Bio has previously expanded its home care product line. The spot patch 'Trudive RX PDRN Live Shot Patch' incorporates Daewoong Pharmaceutical's patented technology 'CLOPAM,' enhancing the strength and stability of the needles until the moment of application. The 'Trudive RX PDRN Roller' is designed in a microneedle system (MTS) format to directly deliver active ingredients to the skin, improving absorption efficiency.
Industry experts predict that competition among companies will intensify as the PDRN market expands. Differentiation in raw material technology, product development capabilities, brand competitiveness, and international business capabilities will be key factors influencing market competitiveness.
An industry insider remarked, "As more consumers choose products based on ingredients, we expect a greater variety of products utilizing PDRN. As the market grows, competition to differentiate raw materials, product forms, and application areas will become even more intense."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.